Category Archives: Genetic Engineering

(Photo : Skye Yayoi Drynan)

While investors who make strategic investments in undervalued companies can transform said business as well as their own portfolio, investors who make strategic investments in companies with an ethical purpose can change the world. The investors that history remembers kindly are not the ones with the highest yields; history looks fondly on the investors who use their economic power to help bring positive to individuals and society at large. Investors who are looking to make a difference have a wide array of industries and companies on a moral mission to choose from.

Biotechnology is a thriving industrywith a plethora of innovative companies using cutting-edge technology to solve the most complex and important health issues of our time. Of course, as the COVID-19Pandemic spread throughout the world over the last few years, investments and innovations in biotechnology are more important now than ever.

Skye Drynanis an investor, entrepreneur, inventor, and thought leader pioneering multiple market-disrupting projects in the biotechnology space, helping people live happier and healthier lives. Drynan has a long history in both investment and biotechnology, always betting on herself. Whether it's excelling on the boys' soccer team as a teenager, becoming the first person in the history of Putnam Investments to transition from their operations division to their investment division, or asking to become the Global Head of Health Care at Credit Suisse at just 27 years old, Drynan knows she can overcome any challenge and reach any goal she sets her mind to.

As a female who has risen to the top of multiple male-dominated industries, Drynan understands what it is like to be underestimated and put in a box. In addition to breaking into multiple 'boys clubs,' Drynan is constantly misunderstood by her peers due to her knowledge about and success in a wide variety of fields. As an inventor with 7 original issued bra patents plus an issued seamless shopping patent called UWIN (U Want It Now), a fashion enthusiast and entrepreneur, and a successful biotech investor who can speak technically about the industry, the depth and width of Drynan's knowledge is unparalleled. Drynan likes to joke that she is just as "comfortable on the red carpet as she is in the boardroom and as a keynote speaker." In addition to the hard work necessary to rise to the top of any field as a technical investor and entrepreneur, Drynan has unfortunately experienced personal and familial health issues over the course of her life. These personal experiences inform Drynan's interest in and excitement about biotechnology.

After graduating from Wellesley and becoming the first person in the history of Putnam Investments to transition from a call center to their investment division, Drynan continued to overachieve and outperform her peers. In her first year in the investment division, Drynan took another risk, speaking truth to power about an investment decision when other employees in her cohort stayed silent about Eurotunnel and Canary Wharf's untenable debt structures. Ultimately being proved right -- helping the company minimize its risks and maximize its returns -- Drynan finished at the top of her class.

Eventually, Drynan would take her newly honed investment skills in order to serve and honor her love for biotechnology; Drynan went to work for Margaret Smith just at the beginning of the genomic boom. After getting special permission to take a genetic engineering course at Harvard and spending two nights a week at MIT labs, Drynan quickly built her technical understanding of the science powering the most important biotechnology innovations. This allowed Drynan to work for a small sell side boutique company in New Jersey building her book of business with some of the largest players in the industry. Her short report on Schering-Plough paved the way for Drynan to join Credit Suisse Asset Management.

Drynan had to prove herself once again, working hard to prove to the CEO that she deserves the job as the Global Head of Healthcare. Drynan bet on herself and took a risk yet again by asking the CEO of Credit Suisse Asset Management to become the Global Head of Health Care. Impressing him with her presentation, her confidence in herself, and her desire to make successful biotechnology investments in companies that were poised to make a positive difference in the world, Drynan secured the job. Stating that he probably would not have given her the job unless she asked, Drynan's willingness to bet on herself bore fruits once again.

This gave Drynan even more experience and legitimacy to take a position at Capital Group, working with some of the most innovative and life-saving biotechnology companies in the world over the last 12 years. During this time, Drynan made partner, became widely recognized as a thought leader in the industry, and has worked with companies to drive the science forward in genetic engineering, cellular therapies, cancer cures, viral treatments, and vaccines.

Recently, Drynan finally made the jump to be her own boss, investing in biotechnology ventures as well as starting her own fashion and tech enterprise. Using her 7 original issued bra patents (+2 patents pending) and 1 issued tech patent (+1 patent pending) , Drynan is now the CEO of House of Skye, a high-tech, high-function, high-fashion brand. Drynan's unique ability to combine the best of fashion and technology has sparked the interests of Carrie Underwood, Lady Gaga, Paris Hilton, Gwen Stefani, Kevin Jonas, Kelly Mi Li and more - all of whom have been seen in House of Skye.

As a thought leader and market-moving investor in biotechnology, we are excited to see how Skye Drynan continues to improve the world with her strategic biotechnology investments as well as her new entrepreneurial projects.

2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Tags:

See the article here:
Skye Yayoi Drynan of House of Skye: The Biotech Investment Thought Leader Talks on the Importance of Betting on Yourself - Tech Times

To print this article, all you need is to be registered or login on Mondaq.com.

Nanotechnology is a vast field which includes a range oftechnologies at the nano scale, being applied to pharmaceuticals,biotechnology, genomics, neuroscience, robotics and informationtechnologies and more. In India it holds importance particularly inthe nanobiotech & nanomedicine segments. The commencement ofnanobiotechnology in India has unfurled a series of questions andchallenges in terms of intellectual property protection. Therefore,it is of immense importance to explore whether the Indian PatentSystem presents suitable atmosphere for appropriate patentprotection in India.

Like any new technology, nanobiotechnology also createsopportunities as well as challenges in adapting the patent regimeto its particular context. This article strives to highlightproblems and challenges faces by Nanobiotechnology invention owingto their multi-disciplinary character, crosssectoral applications,broad claims, as well as difficulties in fulfilling thepatentability criteria of novelty, non-obviousness, and industrialapplication.

Challenges for Nanobiotechnology Invention under Indian PatentsAct 1970

Nanotechnology is a novel and revolutionary branch oftechnology, where reduction in size has demonstrated magnificentresults. Intersection with the field of biotechnology has givenrise to nanobiotechnology. Involvement of living forms and thepotential to meet human necessities have raised issues that areunique to nanobiotechnology. It has emerged as an interdisciplinaryfield of research and development that integrates engineering,physical sciences, and biology through the development of verysmall physical and biological devices using biomimetically inspirednanofabrication techniques1 .

Following challenges are faced under Indian Patent regime inPatenting of Nanobiotechnology Inventions:

According to section 3(d) of the Act, if there is vagueness inthe "particle size", it attracts the possibility of beingincluded in non-patentable subject matter. In case ofnanobiotechnology, the newness of technology is significantlyderived from the reduction in size. The primary ambiguity is lackof a universal definition of nanobiotechnology. The word"nano" encompasses inventions of 100nm in size orsmaller. Pharma industry is likely to be the most beneficiarysegment from nano biotechnology aided research. Nano particleefficacy or accuracy of methods using nano particles for drugdelivery is significantly ruled by particle size which may vary asdifferent drugs are effective with different particle size. Forthis reason, fixing a size limit of 100 nm may rule out thepatenting of such particles under the "nano"regime.5 There is lack of a standard for determinationof the efficacy and quantification of enhancement of efficacy inthe Indian patent regime.

Under this regime, nanotech invention would remain nonpatentableunless the particle size differed in its properties have showedenhanced efficacy. Patentability of drugs would revolve around thereduction in particle size to certify better efficacy, suchcontraventions with provision 3(d) is likely to occur. For example,Abbott Pvt. Ltd. sold an HIV drug Kaletra under brand name"Alluvia". To overcome the storage problems of the drug,Abbott claimed a heat-stable form of the same drug. Apre-opposition was filed by the organization, 'Initiative forMedicines, Access and Knowledge,' under section(d) of thePatents Act 1970.6

Utility requirement is crucial for nanobiotechnologybasedinventions. Nano biotechnology falls under the class of"unpredictable" arts like biotechnology. There is thepossibility of huge variation in the laboratory results andauthentic results when technology such as nanobiotechnology is putto use. In the laboratory stage, it is not possible to determinethe possible impact of external factors on products born out of atechnology. Inoperability of such products may render themnon-patentable as they would fail to comply with the utilityrequirements.7

In addition, the problem-solving approach applied in both Europeand India would render them as not being inventions (thus renderingthe problem insolvable). The case of EMI Group North America Inc vCypress Semiconductor Corp8 provides a better insightinto the requirement. The applicant claimed a patent for aninvention that lacked utility.

The Nanobiotechnology patent can be sought over the process ofpreparing the nanoparticles; the process of transfer of nanoparticles into the patient's body; the medical devices usedetc.9 Here significant question is the distinctclassification of methods as medicinal, surgical, curative,prophylactic, diagnostic and therapeutic and the subject matterthat each of them cover. It is argued that exempting medicalmethods from the purview of patentability is on the one hand, infavour of public policy, whereas allowing patents in this fieldwould draw unwarranted ethical, moral and practical problems andmay also fail to fulfil the industrial applicability criteria.

The problem in the present perspective is whether methods usingnanoparticles constitute diagnostic, surgical or therapeuticmethods. Amendments to the Indian Patents Act 1970, sec 3(i) can beimported from the European jurisdiction which has proposedsignificant amendments to their provisions similar to the IndianPatents law, regarding medical methods. Many of the technologiesbeing currently developed blur the line between non-patentablemethods for treatment and diagnostics practiced on the human bodyon one side and patentable products (substances or compositions)and apparatus used in such activities on the other. Some of theseimportant developments in diagnostics and treatment operate totallyin vitro, others entirely in vivo, some have a combination ofphases in vitro and in vivo, posing patentability questionsconcerning the patentability exception for Methods for treatmentand diagnostic (Hosseini et al., 2011; Daneshyar et al.,2006)10.

Followings are some examples of Nanobiotechology inventionsemployed as drug delivery system in medical methods for treatmentand diagnostic purposes:

Nanoparticles due to their small size have proved to be moreefficient, target specific, water soluble and stable tools in drugdelivery compared with the conventional routes of drugadministration. For decades pharmaceutical sciences have been usingnanoparticles to reduce toxicity and side effects of drugs. Thistechnology raises issues which are in disagreement withintellectual property rights protection and non-commercial laws(such as the environmental laws). In the absence of consonantpatent law provisions, nanotechnology is facing challenges withrespect to the criteria of novelty, inventive step, being capableof industrial application and eligibility of subject matter undersection 3 of the Indian Patents Act 1970.

Nanobiotechnology inventions have generated technologicalrevolution and emerged as a key technology for economic developmentin the twentyfirst century. The use of eco marks on nanobiotechnology products are proposed to ensure environmental safetyand consonance. This would further assist in dealing with thechallenges discussed in the nanobiotechnology products Since patentlaw is technology-specific, providing guidelines to examiners forassessment of patent applications is a good practice and should beencouraged as it would aid in the issuing of better qualitynanobiotechnology patents.

1 Daneshyar SA, Kohli K and Khar RK (2006) Biotechnologyand intellectual property. Sci. Res. Essay. 1, 020-025

2 http://www.indjst.org/March%2012-%20web/38%20paper-6.pdf

3 http://www.law.ed.ac.uk/ahrc/script-ed/vol6-2/sharma.asp.

4 http://www.indjst.org/March%2012-%20web/38%20paper-6.pdf

5 Hosseini et al., 2011; Daneshyar et al.,2006

6 http://www.law.ed.ac.uk/ahrc/script-ed/vol6-2/sharma.asp

7 http://www.law.ed.ac.uk/ahrc/script-ed/vol6-2/sharma.asp

8 "Intellectual Property Rights of Nanobiotechnologyin Trade Related Aspects of Intellectual Property Rights Agreement(TRIPS)" Vol. 6, 5664, 2012, Journal ofBionanoscience

9 http://www.law.ed.ac.uk/ahrc/script-ed/vol6-2/sharma.asp

10 Hosseini SJ, Esmaeeli S and Ansari B (2011) Challengesin commercialization of nano and biotechnologies in agriculturalsector of Iran. Afr. J. Biotechnol. 10, 6516-6521.; Daneshyar SA,Kohli K and Khar RK (2006) Biotechnology and intellectual property.Sci. Res. Essay. 1, 020-025.

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

Original post:
Patenting Of Nanobiotechnology Inventions: Exploring The Challenges Under The Indian Patent Law - Intellectual Property - India - Mondaq

NEW YORK, April 25, 2022 /PRNewswire/ --The global Heating, Ventilation, and Air Conditioning (HVAC) system marketsize is expected to reach USD 219.49 Billion in 2030 and register a revenue CAGR of 5.5% over the forecast period, according to latest report by Reports and Data. Rapid integration of sensors and other similar components into industrial equipment plays a critical role in driving HVAC system marketrevenue growth. A sensor is a type of component when integrated into a device responds to any changes in physical environment and sends output signals. Specific input could be light, heat, motion, moisture, and any other environmental phenomena. The output generated is a signal that is transmitted electronically over a network for reading or further processing.Advanced HVAC system designs incorporate a wide variety of sensors. These sensors aid in measuring and controlling temperature, humidity, air quality, and building pressure. Moreover, it aids designers in identifying critical areas where further improvements can be done. A pressure sensor, for instance, is a critical component used within the HVAC system. It monitors pressure levels within specific zones and measures pressure drop across filters and other components thereby alerting system when maintenance and filter replacement is required.

Rising demand for HVAC systems from food production industry is a key factor driving market revenue growth. Cooling and heating systems play a major role in several industries. However, in food production and storage this is even more important. Food products in storage spaces might get affected by volume of space, quality of air, humidity, and number of workers present in the location. Therefore, it needs to be preserved. Moreover, a properly designed and installed air conditioning unit is essential for food factories. It aids in controlling airborne particulates and odors. In addition, it also minimizes risk of any contamination by keeping food products fresh all time.

Download sample @https://www.reportsanddata.com/download-summary-form/1029

Some Key Highlights from the Report

Ask for Customize Research Report @https://www.reportsanddata.com/request-customization-form/1029

To identify the key trends in the industry, research study athttps://www.reportsanddata.com/report-detail/hvac-system-market

For the purpose of this report, Reports and Data has segmented the HVAC system market based on type, ventilation devices, cooling equipment, application, and region:

Buy Premium Research Report @https://www.reportsanddata.com/report-pricing/1029

Explore Trending Research Reports by Reports and Data:

Single-Ply Roofing Market: By Membrane Type (Thermoplastic, Thermoset, Others), By Installation Method (Ballasted System, Mechanically Attached System, Fully Adhered System, Others), By End-use (Industrial, Commercial, Residential), and By Region , Forecasts to 2030

Liquid Applied Membranes (LAMs) MarketSize, Share, Trends, By Product (Bituminous, Cementitious, Others), By Application (Building Structure, Roofing, Others), By End-Use (Commercial, Residential, Others), and By Region Forecast to 2030

Fiber Cement Board MarketSize, Share, Trends, By Material (Sand, Portland Cement), By Product (High Density Board, Medium Density Board), By Production Process, By Application (Siding, Roofing, Others), By End-Use, and By Region Forecast To 2030

Automated Barriers and Bollards Market, By Type (Push Button, Remote Controlled, RFID Tag Readers, Loop Detectors, and Others), By Application (Residential, Commercial, and Industrial), and By Region Forecast to 2030

Fly Ash MarketSize, Share, Trends, By Type (Class F, Class C), By Application (Bricks & Blocks, Portland Cement & Concrete, Road Construction, Agriculture, Others), and By Region Forecast to 2030

Water Quality Monitoring Equipment MarketSize, Share, Trends, By Type (pH Testing, Conductivity Sensors, TOC Analyzer, Dissolver-Oxygen Analyzer, Hydrogen Sulfide Analyzer, Others), By Equipment Type, By Application, and By Region Forecast to 2030

Flooring Market, By Type (Non-resilient, Resilient, Soft Covering), By Application (Healthcare Buildings, Education Buildings, Commercial, Residential Buildings, Sports Complexes), By Material (Wooden, Vinyl and Rubber, Tiles), and By Region Forecast to 2030

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. For more information, visitwww.reportsanddata.com.

Contact:JohnWHead of Business DevelopmentReports And Data | Web:www.reportsanddata.comDirect Line: +1-212-710-1370E-mail:[emailprotected]LinkedIn|Twitter|Blogs

Read Latest Press Release @https://www.reportsanddata.com/press-release/global-hvac-system-market

Read Exclusive Blogs by Reports and Data -

Top 10 Key Players in Digital Notepad Market with Innovative and Novel FeaturesTop 10 Key Players in Genetic Engineering in Agriculture Market with Novel Technology SolutionsTop 10 Leading Chromebook Models with Ease-of-Management Features for Seamless Business OperationsWorld's Top 10 Companies Ruling the Plant-based Meat Sector

SOURCE Reports And Data

Excerpt from:
HVAC System Market Size To Reach USD 219.49 Billion In 2030 | Rapid Adoption Of Energy-Efficient Air Conditioners In Consumer Products Is A Major...

Nearly a dozen agricultural organizations are continuing to encourage the revising of gene editing regulations. Oversight of genetically engineered food animals is currently handled by the U.S. Food and Drug Administration (FDA). Ag groups are pushing for the U.S. Department of Agriculture (USDA) to assume responsibility of animal biotechnology. In a letter addressed to Agriculture Secretary Tom Vilsack, the organizations point out the necessity in updating the regulatory approach to gene editing in livestock.

The FDAs current regulatory approach an approach that producers, other stakeholders, and Congress have repeatedly expressed concern with will only stifle U.S. producers access to much-needed innovations, the letter states. Academics, developers, and investors are unlikely to make the significant investments needed to research and develop agricultural innovations if they do not have clear, predictable criteria to achieve enforcement discretion and reasonable market access.

Signatories of the letter include the National Cattlemens Beef Association, National Milk Producers Federation, American Farm Bureau Federation, and the National Association of State Departments of Agriculture. The groups assert that changes to gene editing regulations are needed to better combat a variety of issues including diseases and challenges related to climate change. USDA has been working to advance a framework to establish a more modernized approach to regulating gene editing technologies in animal agriculture. The groups expressed support for USDA efforts in advancing the proposed rulemaking for the Regulation of Movement of Animals Modified or Developed by Genetic Engineering.

Gene editing technology offers livestock producers the opportunity to address the serious sustainability, animal health, and food security challenges facing our food supply in the 21st century, the groups note in the letter. However, this potential can only be achieved if we have federal policies that are risk-and science-based, and that permit the meaningful adoption of these products by producers, supply chains, and consumers.

Related

Read more from the original source:
Industry Groups Encourage USDA Takeover of Gene Editing Regulations - AgNet West

New technologies and production processes in the food industry have led to novel foods becoming increasingly important to both food manufacturers and the consuming public worldwide. This is very much the case across a number of jurisdictions in Southeast Asia.

Novel foods refer to new food production processes, foods, and ingredients that have not yet been commonly used for human consumption, so these innovative foods require safety assessments before companies can produce and market them. While rules for these safety assessments are already part of novel food regulations in several other jurisdictionssuch as the novel food regulations in the United Kingdom and European Union adopted in 2003, and the major reform of food safety laws in the United States passed in 2011 under the Food Modernization Actsimilar rules governing the assessment of novel foods are relatively new or yet to be introduced in many parts of Asia.

Nevertheless, it is important to understand the laws and practices that apply to safety assessments and the process of bringing novel foods to market in jurisdictions in the region. This article provides some clarity in this regard by summarizing important practical information on novel foods and the relevant required safety assessments in Indonesia, Thailand, and Vietnam.

Indonesia

Process and Timeline

Before submitting an application for novel food safety assessment, the applicant or a representative should first consult with BPOMs Directorate of Processed Food Standardization. This consultation can help the applicant identify the data requirements for submission.

For obtaining approval of novel foods, applicants must submit the required items through the directorates online submission system. BPOM will then check the application to verify its completeness, and will contact the applicant within five working days either to confirm that the submission is complete or to direct the applicant to rectify any shortcomings.

Once all requirements have been fulfilled, BPOM is to assess the application within 85 working daysor around 46 months in practice.

Required Documents

The application requirements differ depending on the category of novel food. There are two main categories:

Thailand

Process and Timeline

Seeking approval for novel foods consists of two stages.

In this stage, the applicant submits safety data to one of four safety assessment organizations accepted by the FDA. The maximum or estimated duration of this step depends on the organization:

Novel foods that contain any ingredient derived from a genetically modified organism (GMO) must undergo a BIOTEC review.

To apply for the FDAs approval of a novel food, the applicant must submit the letter from the safety assessment organization, along with other relevant documents, to the FDA via their online system. The FDA will consider the application and make a determination within 40 business days.

Required Documents

Vietnam

A genetically modified food contains one or several genetically engineered ingredients. New food additiveswhile not legally definedinclude new combinations of permitted food additives, food additives not included in the permitted list, and food additives included in the permitted list but used outside of the permitted categories.

A genetically modified food contains one or several genetically engineered ingredients. New food additiveswhile not legally definedinclude new combinations of permitted food additives, food additives not included in the permitted list, and food additives included in the permitted list but used outside of the permitted categories.

Self-declaration: None

Registered product declaration: USD 70

Process and Timeline

Conventional Foods. Every food product sold in Vietnam must have a declaration that it meets regulatory standards. For many types of food, a self-declaration procedure covers this requirement. However, some foods also require additional inspection and approval from the Ministry of Health via a registered product declaration.

GMOs. Food products based on GMOs that are on the Ministry of Agricultural and Rural Developments list of edible GMOs undergo the same approval procedure as other conventional food products. However, food products based on GMOs not on this list must first obtain certification of the GMOs eligibility for use as food before undergoing the approval procedure for conventional food products.

In order to apply for certification, Vietnams Council of Food Safety must have concluded that the GMO has no inordinate risks for human health, or the GMO must have been approved for use as food by at least five developed countries, with no adverse incidents having occurred.

If one of these conditions is met, the application can be submitted to the relevant department in the Ministry of Agricultural and Rural Development. Within seven working days of receiving a submission, the department will acknowledge the validity of the application or request additions.

Valid applications will then be appraised by the Genetically Modified Food Safety Councilan advisory council composed of representatives of the Ministries of Industry and Trade; Science and Technology; Agriculture and Rural Development; Natural Resources and Environment; and Health, in addition to other experts. For GMOs that have already been approved for use as food by at least five developed countries, without any recorded adverse incidents, appraisal of the application takes 60 days. For other GMOs, the maximum appraisal duration is 180 days.

Within 30 days of obtaining the appraisal results, the minister of the Ministry of Agricultural and Rural Development will either certify the GMOs eligibility for use as food, or issue a refusal clearly stating the reason.

Required Documents

Applications for certification of a food product as an edible GMO must include the following items:

If the applicant has any other unpublished reference or research materials, assessments, test reports, or scientific figures concluding that the genetically modified organisms do not negatively affect human health, those items should be included in the application.

Conclusion

New foods and ingredients are highly regulated in countries around the world, regardless of whether a jurisdiction has specific laws on novel foods. There are some common regulatory approaches and practices, but even in a single region such as Southeast Asia the rules and processes can vary. Indonesia, Thailand, and Vietnamthree especially active and well-developed regulatory regimes for food in the region, offer compliant food producers and importers a chance to access local consumers and markets. By first recognizing the requirements and regulations in these jurisdictions, and then seeking local expertise that can ensure the process is done correctly, businesses and investors can avoid costly interruptions or delays as they bring their products to market.

Here is the original post:
Novel Food Safety Assessments in Indonesia, Thailand, and Vietnam - Lexology

We went on a hunt for the coolest (and spookiest) stories about bringing vulnerable animals back from the brink of extinction or, in some cases, bringing them back from the dead.

De-extincting the Tassie tiger: an Australian Jurassic Park?

In a stunning announcement in March, the University of Melbourne announced it had received $5 million in funding for a new research lab, the Thylacine Integrated Genomics Research Lab (TIGRR), which will primarily look to bring back the extinct thylacine (Tasmanian tiger) using genetic engineering and cloning techniques.

Once abundant in Tasmania, the tigers were hunted to extinction by European settlers who thought they were killing their livestock.

The ambitious new project will take a thylacine genome, salvaged from a preserved specimen, and use it as a map to re-engineer the genome inside a living cell from the creatures closest living relative, the Dunnart. Then, it will in theory clone a living thylacine from that living cell.

But, to paraphrase Jeff Goldblum, is this a case of spending so much time wondering whether they could, they never stopped to think whether they should?

Read more here.

Lost South American wildflower named extinctus rediscovered (but still endangered)

In a rare but beautiful case of redemption, the orange tropical wildflowerGasteranthus extinctus,endemic to the Andean foothills in Ecuador, was thought to have gone extinct 40 years ago.

But in a stroke of luck, a team of researchers who set out in hopes of rediscovering the plant managed to find a specimen growing, proving that its still clinging on (though still perilously endangered).

We walked into Centinela thinking it was going to break our heart, and instead we ended up falling in love, said one of the lead researchers.

Get an update of science stories delivered straight to your inbox.

Read the full article here.

Bringing back the iconic woolly mammoth

Back in 2017, scientists from Harvard University stunned the world when they announced plans to bring back the iconic woolly mammoth.

These iconic, massive elephant-like creatures had shaggy fur that helped them brave the frosty wilds of the last Ice Age.

De-extincting the mammoths, the scientists said, would be possible because mammoth DNA remains in frozen carcasses found buried in the permafrost in places like Siberia. They say theyre going to use elephant DNA to help patch up the holes, and create a living mammoth cell, which they will implant into an elephant to carry to term, giving birth to a real life woolly mammoth.

But, why do it?According to Revive and Restore, a genomic research and restoration project, the absence of the woolly mammoths from the tundra stopped the compaction of snow, meaning extreme winter cold didnt penetrate the soil, leading to the accelerated melting of the permafrost.

So, the theory goes, these new mammoths will help reverse the melting of these ice stores that are full of greenhouse gases.

Read on for more.

Bringing back the Christmas Island rat

It might be a slightly less iconic species, but the Christmas Island rat was yet another fatality of European expansion, vanishing from the island 119 years ago because of diseases brought from the strange, foreign land.

This rat still has many living relative species, making it potentially a model species for this kind of de-extinction.

Read on for more.

Read the rest here:
Wrap: four organisms that could be brought back from the brink of extinction (and beyond) - Cosmos

GMO debate is not over

In his op-ed Saving the planet one bite at a time, (April 7), Prof. Sylvain Charlebois says the new United Nations Intergovernmental Panel on Climate Change (IPCC) report is worth the read but it seems he did not actually read it himself. Charlebois says, The report sees global trade and genetic engineering as part of the solution, but the report doesnt even mention genetic engineering (genetically modified organisms or GMOs). Yet he then states, it is time to put the anti-GMO rhetoric to rest. Whatever reason he has for making this passionate statement, the IPCC is not it, and readers deserve correct information. Falsely reporting on the IPCC content trivializes the serious challenge before us. Furthermore, this attempt to shut down debate over GMOs comes at a time when we need more debate, not less: as the Canadian Food Inspection Agency and Health Canada are proposing to remove environmental and food safety assessments for some genetically engineered seeds and foods.

Lucy Sharratt, co-ordinator, Canadian Biotechnology Action Network (CBAN)

Brott deserves a statue

The sudden recent death of Boris Brott in such a tragic manner is truly heartbreaking. That it should happen on a street in Hamilton, the city he loved so well, is especially painful.

Boris Brott was a world renowned maestro, and a strong proponent of this city. The enthusiasm and obvious joy he brought to his performances was always uplifting to witness.

I was lucky to see him perform here in Hamilton and more recently at the National Arts Centre in Ottawa. His enthusiasm, energy and sense of fun was always evident.

I think a fitting and appropriate tribute to Boris Brott would be to have his likeness in a statue erected in Gore Park, honouring his decades long musical contributions to Hamilton. Honouring him this way would also promote his legacy of a love for music.

Perhaps it might replace the contentious statues of John A. Macdonald or Queen Victoria. The loss of a person of Brotts stature deserves a monument at the centre of this city.

Marion Shynal, Stoney Creek

Standardize traffic lights

Who knows when a green light with a red flashing hand signal is going to yellow and one second later to red? Or countdown lights some turn red at 0; other countdowns go from 0 to a red hand signal for you to guess at how long you have to go through the intersection safely. A quick glance into your review mirror tells you that the car behind you is on your bumper; to make a quick decision to stop could end up in a collision. Split second decision. I hate it! You slow down nearing an intersection not knowing weather you can safely make it through the light only having to speed up as the light hasnt yet changed and the guy behind you is honking his horn pushing you through. Then you worry if this was a red-light camera intersection. I ask myself every day, why cant Hamilton synchronize all the traffic lights for continuity, so that every driver knows when to slow down to stop?

Saving mine for buck-a-beer

The letter writers complaining about getting a refund on the licence stickers are getting tiring. Really? I never got a red cent back from their beloved Liberals, in fact I was gouged enough on everything from electricity to public services to make up for a centurys worth of overpayment to their provincial coffers.

I, for one, appreciate that I dont have to spend money on stickers for my vehicles and was grateful to get my refund. You want to donate your refund to Del Duca or any other cause, knock yourself out. Im saving mine for buck-a-beer.

In praise of journalists

If not for journalists, we would not have found out that the abundance of rapid tests in Ontario were given to private schools. In fact they were given more tests than LTC homes and paramedics put together. I am a proud supporter of my local newspaper and thankful for the truth seekers out there. Keep up the good work the general public needs to know the truth

Robin Magder Pierce, Hamilton

Depraved Russian soldiers

For the children, written in Russian, on the side of an exploded missile, in the midst of dozens of Ukrainian dead. Unarmed civilian, women, children and aged. Can we imagine much that is more barbaric, uncivilized and depraved? We wonder if this dedication was the sick humour of the commanding officer, or was a suggestion from petulant Putin personally. It certainly leaves no doubt as to their evil intentions. I shall never visit Russia.

Edward A. Collis, Burlington

Superrich of the world, unite!

Regarding Liberal-NDP deal will mean major tax hikes (April 1): The manifesto of the 21st century: Superrich of the world, unite!

Nicholas Christoforou, Ancaster

See more here:
Opinion | April 16: Russian barbarism, a statue of Boris, standardize traffic lights and other letters - Hamilton Spectator

Chinese leader Xi Jinping helda grand ceremonyon April 8 to celebrate the success of the Beijing Olympics. Perhaps it is just because of the success Xi was bragging about thatmodern Olympism, once admired by generations of people from around the world, is dead.

The cause of death of modern Olympism is twofold: corruption and hyper-and-unfair-politicization which includes the ascendance of nationalism.

Few people are so naive as to believe that the Olympics are, or could ever be, devoid of politics. Indeed, since its inception, the modern Olympic Games have become part of geopolitical history, often reflecting political tensions between nation-states.

At the 1920 Summer Olympics in Antwerp, Belgium the first Games held after World War I nations that lost in the war, such as Germany, were banned from participating. This punitive measure would have violated the principle of political neutrality enshrined in the current version of the Olympic Charter, although early versions of the Charter did not contain such a stipulation.

Sixteen years later, perhaps in part as an act of revenge or vindication, a re-emerging Germany transformed the event into a nationalistic and ideological contest as the host of the 1936 Summer Olympics in Berlin.

During the Cold War, international sports competitions were used as a vehicle for regimes to declare the superiority of their respective political systems. In recent years, the politicization of the Olympic Games has escalated to an unprecedented level, mainly at the hands of Russia and China.

Chinas communist regime exploited the 2008 Beijing Olympics to the fullest extent possible. The Games were a political project designed to demonstrate, both domestically and abroad, the rise of China under the leadership of the Chinese Communist Party (CCP).

The 2014 Sochi Winter Olympics were staged in large part to display the strength of Russian President Vladimir Putin, who used the Games as an opportunity to bolster the image of Russias strength in the lead-up to the authoritarian states annexation of Crimean in February and March of that year.

Thepoliticizationof the Olympic movement was always inevitable, but it is itsunfair politicizationthat has killed modern Olympism.

Such unfair politicization was on full display at the 2022 Beijing Winter Olympics. The Chinese government extensively politicized the 2022 Beijing Olympics while simultaneously slandering dissenting voices of Chinese human rights victims, activists and groups, and the democratic governments of other countries. It claims that such individuals and groups are politicized and contradict the Olympic spirit.

According to the Olympic Charter, the goal of the Games is to place sport at the service of the harmonious development of humankind, with a view to promoting a peaceful society concerned with the preservation of human dignity.

Genocide such as is happening to Uyghurs in Xinjiang is the antithesis of the harmonious development of humankind, and forced labor tramples on human dignity, rather than preserving it.

Ouracts of politicization, meant to defend universal fundamental ethical principles as set forth in the Charter such as peacefully publicizing and protesting the past and present atrocities committed by the CCP were prohibited in Beijing and across China.

The athletes, warned in advance by Chinese officials to remain silent on political matters while in China, literally feared for their freedom and safety if they spoke out.

The modern Olympics have long become a hyper-nationalized event. The Olympic Charter stipulates that the Games are competitions between athletes in individual or team events and not between countries. However, in reality, no Olympic athlete stands alone. Every Olympian is required to be a national of the country of the National Olympic Committee which is entering such competitor.

Olympic athletes are part of teams representing nations. The modern Olympic Games have turned into a competition between nations. Victory, measured by medal count, glorifies and validates the nation and its ruling regime, and is used to purportedly demonstrate the greatness of the nations leader.

Just like Adolf Hitler, Xi wanted the 2022 Beijing Winter Olympic Games to validate and demonstrate Chinese superiority and his own greatness as Chinas leader. He also wanted the Chinese flag, raised and waved around during the Games, to mobilize nationalist sentiment.

The Olympics have become a dangerous instrument of nationalism, which in China means Han chauvinism. As such, anyone in China who might have wanted to politicize the 2022 Games by speaking out about and defending universal ethic principles, such as protesting the genocide of Uyghurs in Xinjiang, would have been deemed an enemy of Xi, the CCP regime, and even the entire nation.

This is the anthesis of fair play, which is a core tenet of the Olympic spirit.

Moreover, the fact that the modern-day Olympics have become a multibillion-dollar business operation virtually ensures that corruption is the rule rather than the exception. This includes doping and, eventually, genetic engineering of competitors especially by depraved, morally-bankrupt totalitarian states like China and Russia.

Compared to democratic nations, authoritarian states like China and Russia also devote vastly more resources to training athletes and bribing the IOC to host the Olympics. These countries give out huge bonuses to medalists who bring glory to their country. And, of course, there are lucrative business opportunities that follow.

The Olympic Games have become one-third politics, one-third money, and one-third competition.

The spirit of modern Olympism has suffered a gradual death of a thousand cuts, due primarily to the intense and ever-increasing politicization of the Games and fueled by the rampant corruption of participating and hosting countries (some more than others) and the IOC itself.

If the integrity of modern Olympism can ever be redeemed, certain changes must take place:

First, competition must be between individual athletes. Naturally, every athlete has his or her own roots, nationality, and citizenship, but none of these factors should be a prominent part of the Games. There should be no national teams, nor should any national flags be raised during the Games.

Second, any politicization of the Games must be carried out in a fair, free, and peaceful manner.

Third, the host country must ensure freedom of expression and freedom of press for all Olympic participants and the media. Any complaints about breaches of these freedoms must be investigated, and, if substantiated, the host country must face severe consequences.

Unless major improvements are made to ensure that the Olympics are about athletic greatness and not political prowess or nationalistic fervor, the trend of declining interest in the Olympic Games will inevitably continue.

Read the original:
Unfair Politicization, Corruption, and the Death of Modern Olympism - The Globe Post

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR Get Rating) have earned a consensus rating of Buy from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.00.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Jasper Therapeutics in a report on Monday, February 28th. They set an overweight rating and a $10.00 price target on the stock. Credit Suisse Group cut their price target on Jasper Therapeutics from $15.00 to $10.00 and set an outperform rating on the stock in a report on Friday, February 25th. Finally, Zacks Investment Research raised Jasper Therapeutics from a sell rating to a hold rating in a report on Thursday, January 20th.

JSPR stock traded down $0.13 during midday trading on Tuesday, reaching $2.72. The company had a trading volume of 62,997 shares, compared to its average volume of 85,363. The stocks 50 day moving average price is $3.58. Jasper Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $18.88.

Jasper Therapeutics Company Profile (Get Rating)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.

See Also

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of Buy from Analysts - Defense World

New Delhi (India), April 20: India is preparing to become a global player in the life sciences, fueled by its recent economic boom and a drive to diversify its portfolio with biotechnology. In this article, we look at Indias biological research history, current situation, and expected future growth. Indias greatest difficulty in realizing its ambitions will be to educate, recruit, and support the next generation of scientists. Such issues concern the United States and Europe, but they are especially acute in developing countries that are rushing to achieve scientific brilliance at a rate that may be faster than their current educational and faculty support institutions would allow.

Biotechnology is an important component of Indias national health agenda and a potential source of economic growth. Recognizing the critical role that biology will play in the twenty-first century, the Indian government is expanding and establishing several new biological research institutes, which will result in the creation of several new roles for life science experts. Funds are increasingly becoming accessible for cutting-edge equipment, reducing the formerly significant discrepancy in support facilities between Indias best research institutes and those in the United States and Europe. India is becoming a more attractive site for biological research and a rich base for emerging biotechnology businesses. However, until India attracts and encourages its 6 brightest young people to pursue research, success will not be proportional to the amount of money invested.

Many academic institutions and businesses in the United States and Europe are looking to collaborate with India, the worlds largest democratic country. Having Indian scientists on their faculty or postdoctoral fellows/graduate students in their laboratories has long been beneficial to Western institutions (perhaps benefitting more than India itself). Western scientists, on the other hand, have a limited understanding of Indias scientific and educational systems.

There are about 800 medical and healthcare R&D institutions in India, as well as 575 medical colleges, 350 universities, over 15,000 pharmaceutical and biopharmaceutical enterprises, and an uncountable number of healthcare entities and diagnostics laboratories that handle biomedical material. To govern biotechnology research, there are biosafety committees, a review committee on genetic manipulation, and a genetic engineering advisory group.

Companies are actively working on pharmaceuticals that must be used for an extended period of time, a departure from the conventional idea of minimal medication and quick recovery.

At 2003, USA Today reported on hundreds of diseases caused by humans coming into touch with germs in US biolabs in the US and other parts of the world, including the Middle East, Southeast Asia, CIS countries, and Africa. To evade the gaze of the law, its reasonable to imagine that US biolabs have completely moved such risky operations out of the US and into these other regions.

Given the lack of rules and oversight in India, American biolabs appear to have free reign to undertake trials and experiments. Even from Indian official inspection authorities, most such operations are well guarded and kept secret. Because American biolabs are concerned about public backlash and class action lawsuits in the United States, they have decided to conduct their trials in less regulated third-world nations such as India.

For example, India welcomes foreign investment and is ready to turn a blind eye when biotech companies undertake dangerous trials on an uninformed, ignorant, and illiterate population. Its worth noting that the people chosen for trials are frequently from the poorest parts of society, with little knowledge of the law, the testing procedure, or access to legal counsel.

According to the Indian defence establishment, the Surat plague in 1994, which killed 55 people and forced half of the citys population to flee, was an example of biolab leakage. Various news sources from the time mention the American CDC. There were allegations that CDC labs in Almaty, Kazakhstan, had created a germ with an additional protein ring.

For example, at a cost of $107,000, the US Defense Threat Reduction Agency financed three-year research effort on the highly pathogenic Avian Influenza virus was carried out in Haryana, Kerala, and Odisha. The projects purpose was to gather HPAI positive samples in order to assess the diseases spread and strength.

This isnt a one-off occurrence. At 2019, investigations showed that the US Centers for Disease Control and Prevention (CDC) had secretly financed Nipah Virus research in a BSL2 laboratory in Karnataka. Because the virus is so deadly, these testing can only be performed in a BSL4 level lab.

Between 1967 and 1973, the US Army collaborated with the Bombay Natural History Society in India to perform a Migratory Animal Pathological Survey. The Indian Parliament eventually objected, citing concerns that the study could be used for bio-warfare, forcing the initiative to be halted.

The Northeastern states of Assam, Manipur, Meghalaya, and Tripura were also targeted by American laboratories. The US Ministry of Defenses Defense Threat Reduction Agency conducted an Ebola research project in these areas, collecting human and bat blood. The National Center for Biological Sciences in Bangalore conducted the experiments.

It is all too clear that India, like other third-world and developing countries, is a puppet in the hands of US biopharmaceutical companies that are abusing regulatory procedures and abusing their financial power to do whatever they want, regardless of the repercussions. This must be changed. India should adopt tighter restrictions and control for such facilities conducting trials or research in the country in order to protect India from suffering from potential biological dangers.

Read the original here:
India Biolabs Need Stringent Regulations - ED Times